YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names. Continue Reading
For Immediate Release Chicago, IL – September 23, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financia…
Clinical readouts are among the most important catalysts for biotechnology stocks, as study results can materially shift investor expectations about a drug candidate's efficacy, safety, regulatory prospects and commercial potential. Positi…
You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know about: It's a healthcare investor. Joh…
* Rapport Therapeutics press release [https://seekingalpha.com/pr/20607480-rapport-therapeutics-reports-second-quarter-2026-financials-and-provides-business-update] (RAPP [https://seekingalpha.com/symbol/RAPP]): Q2 net Loss was $56.6M, as…
Key Points COO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on a weighted average price of $41.58 per share. This sale represented 6.2% of Gault's direct holdings, reducing her position from…
Is RAPP a good stock to buy? We came across a bullish thesis on Rapport Therapeutics, Inc. on TradersPro's Substack. In this article, we will summarize the bulls' thesis on RAPP. Rapport Therapeutics, Inc.'s share was trading at $38.26 as…
In late May 2026, analysts BTIG and Truist highlighted Rapport Therapeutics’ RAP-219 program after the company reported progress toward Phase 3 trials, supported by earlier Phase 2a follow-up data. An interesting angle is how RAP-219’s dua…
Rapport Therapeutics, Inc. (NASDAQ:RAPP) is one of the 10 Stocks That Have the Potential to Rise 1000%. On May 21, 2026, BTIG raised the firm’s price target on Rapport Therapeutics, Inc. (NASDAQ:RAPP) to $65 from $53 and maintained a Buy r…
On April 17, 2026, Third Rock Ventures V, L.P., a 10% owner of Rapport Therapeutics, Inc.(NASDAQ:RAPP), reported the direct sale of 426,005 shares in an open-market transaction valued at approximately $17.18 million, according to a SEC For…
(RTTNews) - Rapport Therapeutics, Inc. (RAPP) reported that its investigational therapy RAP-219 continued to deliver clinically meaningful benefits even after dosing ended, with patients experiencing a 90% median reduction in seizures duri…
Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clinical seizures over baseline in weeks 13…
Cormorant Asset Management disclosed a buy of 2,361,260 shares of MoonLake Immunotherapeutics(NASDAQ:MLTX) in its February 17, 2026 SEC filing, an estimated $27.86 million trade based on quarterly average pricing. What happened According t…
On February 17, 2026, Cormorant Asset Management disclosed in a regulatory filing that it sold its entire stake in Arcellx(NASDAQ:ACLX), an estimated $63.63 million transaction based on last-disclosed position values. What happened Accordi…
Cormorant Asset Management initiated a new position in Olema Pharmaceuticals(NASDAQ:OLMA), buying 2,750,000 shares worth $68.75 million in the fourth quarter, according to a February 17, 2026, SEC filing. What happened Cormorant Asset Mana…
Key Points Cormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 shares in the fourth quarter. The value of the position was $68.75 million at quarter-end. The new position places Olema outside C…
Key Points Cormorant Asset Management sold 50,000 shares of PRAX in the fourth quarter; the estimated trade size was $9.31 million based on quarterly average pricing. Meanwhile, the quarter-end value of the PRAX position increased by $227.…
* Rapport Therapeutics press release [https://seekingalpha.com/pr/20430346-rapport-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides] (RAPP [https://seekingalpha.com/symbol/RAPP]): Q4 GAAP EPS of -$0.72…
此次合作依托Tenacia在中枢神经系统（CNS）药物开发与商业化方面的专长，加速RAP-219在美国及全球的开发进程 Tenacia获得大中华区RAP-219开发和商业化的独家权利，针对病症包括局灶性发作癫痫和双相躁狂等适应症 Rapport将获得2000万美元的现金预付款，最高可达3.08亿美元的潜在开发与商业化里程碑款项及其他付款，以及个位数中段到十几中段的分级特许权使用费 波士顿和上海, March 10, 2026 (GLOBE NEWSWIRE) -- 致力于为…
Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents 0.31% of Cormorant’s reportable 13F ass…
Key Points Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents 0.31% of Cormorant’s reportable 13F ass…
Rapport Therapeutics, Inc. BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of…
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’ disease severity RAP-219 demonstrated…
Rapport Therapeutics, Inc. (NASDAQ:RAPP) is among the best fast money stocks to buy now. Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Rapport Therapeutics, Inc. (NASDAQ:RAPP) with a price target of $77, im…
(RTTNews) - Several clinical-stage biotech companies saw strong after-hours momentum on Friday, driven by upcoming trial data releases and pipeline updates. Shares of biopharmaceutical company MBX Biosciences Inc. (MBX) surged 33% in after…
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. On Friday, LB Pharmaceuticals', Ran Nussbaum,…
[Sign for Wall Street in New York City] Pharrel Wiliams Rapport Therapeutics (NASDAQ:RAPP [https://seekingalpha.com/symbol/RAPP]) traded higher on Tuesday after Truist launched its coverage with a Buy recommendation and a $44 price target,…
Shares of Rapport Therapeutics RAPP surged 61.6% in a week after the company reported positive top-line data from a mid-stage study of its lead candidate, RAP-219, in patients with drug-resistant focal onset seizures (FOS), a type of epile…
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision…
[Financial advisor interacts with a digital interface displaying machine learning data insights.] QuantumScape Corporation (NYSE:QS [https://seekingalpha.com/symbol/QS]) rallied in morning trading on Thursday as it took back ground lost ov…
* Rapport Therapeutics (NASDAQ:RAPP [https://seekingalpha.com/symbol/RAPP]) priced [https://seekingalpha.com/pr/20227241-rapport-announces-pricing-of-public-offering-of-common-stock] an underwritten public offering of 9.62M shares at a pub…
BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision…
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT SNTG [htt…
[ALPHA - word on the background of cash dollar bills] Zhanna Hapanovich Factors such as fewer initial public offerings and passive investing have led to a situation where there is "no alpha" left in stock markets, according to an Apollo ec…
The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.21%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.25%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.46%. September E-mini S&P futures (ESU25) rose +0.25%, and Septe…
The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.21%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.25%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.46%. September E-mini S&P futures (ESU25) rose +0.25%, and Septe…